Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$52.8
Market cap
$107.05B
P/E Ratio
N/A
Dividend/share
$2.4
EPS
-$3.25
Enterprise value
$153.14B
Bristol Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease,
Highlights
The company's revenue rose by 2.9% YoY and by 2.1% QoQ
Bristol Myers Squibb's equity has decreased by 47% YoY but it has increased by 3.2% from the previous quarter
BMY's debt is up by 39% year-on-year but it is down by 6% since the previous quarter
Bristol Myers Squibb's EPS has shrunk by 186% YoY and by 5% QoQ
The net income has dropped by 182% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of BMY
Market
Valuations
Earnings
Shares outstanding
2.03B
Market cap
$107.05B
Enterprise value
$153.14B
Price to book (P/B)
6.29
Price to sales (P/S)
2.3
EV/EBIT
N/A
EV/EBITDA
42.6
EV/Sales
3.29
Revenue
$46.51B
EBIT
-$6.43B
EBITDA
$3.6B
Free cash flow
$12.95B
Per share
Balance sheet
Liquidity
EPS
-$3.25
Free cash flow per share
$6.39
Book value per share
$8.39
Revenue per share
$22.94
TBVPS
$21.45
Total assets
$94.65B
Total liabilities
$77.58B
Debt
$52.39B
Equity
$17.02B
Working capital
$3.63B
Debt to equity
3.08
Current ratio
1.16
Quick ratio
0.78
Net debt/EBITDA
12.82
Margins
Efficiency
Dividend
EBITDA margin
7.7%
Gross margin
75.4%
Net margin
-14.1%
Operating margin
-13.8%
Return on assets
-6.9%
Return on equity
-28.5%
Return on invested capital
-11.1%
Return on capital employed
-9%
Return on sales
-13.8%
Dividend yield
4.55%
DPS
$2.4
Payout ratio
N/A
BMY stock price
How has the Bristol Myers Squibb stock price performed over time
Intraday
0.61%
1 week
-1.79%
1 month
8.87%
1 year
-6.73%
YTD
2.9%
QTD
2.05%
Financial performance
How have Bristol Myers Squibb's revenue and profit performed over time
Revenue
$46.51B
Gross profit
$35.06B
Operating income
-$6.42B
Net income
-$6.54B
Gross margin
75.4%
Net margin
-14.1%
The net income has dropped by 182% year-on-year and by 6% since the previous quarter
BMY's net margin has dropped by 180% year-on-year and by 4.4% since the previous quarter
The operating income has dropped by 174% year-on-year and by 10% since the previous quarter
The operating margin has dropped by 172% year-on-year and by 8% since the previous quarter
Growth
What is Bristol Myers Squibb's growth rate over time
Valuation
What is Bristol Myers Squibb stock price valuation
P/E
N/A
P/B
6.29
P/S
2.3
EV/EBIT
N/A
EV/EBITDA
42.6
EV/Sales
3.29
Bristol Myers Squibb's EPS has shrunk by 186% YoY and by 5% QoQ
BMY's P/B is 57% above its 5-year quarterly average of 4.0 and 31% above its last 4 quarters average of 4.8
Bristol Myers Squibb's equity has decreased by 47% YoY but it has increased by 3.2% from the previous quarter
The price to sales (P/S) is 28% less than the 5-year quarterly average of 3.2
The company's revenue rose by 2.9% YoY and by 2.1% QoQ
Efficiency
How efficient is Bristol Myers Squibb business performance
Bristol Myers Squibb's ROA has plunged by 183% YoY and by 6% from the previous quarter
Bristol Myers Squibb's return on sales has shrunk by 172% YoY and by 7% QoQ
BMY's return on invested capital has dropped by 163% year-on-year
The ROE has contracted by 24% from the previous quarter
Dividends
What is BMY's dividend history
DPS
$2.4
Dividend yield
4.55%
Payout ratio
N/A
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Bristol Myers Squibb financials performed over time
BMY's total assets is 22% greater than its total liabilities
The total liabilities has increased by 26% year-on-year but it has declined by 6% since the previous quarter
Bristol Myers Squibb's current ratio has decreased by 17% YoY but it has increased by 4.5% from the previous quarter
The company's debt to equity has surged by 161% YoY but it fell by 9% QoQ
Bristol Myers Squibb's equity has decreased by 47% YoY but it has increased by 3.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.